EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

8 November 2024
EMA/CVMP/495258/2024
Veterinary Medicines Division

MRL summary opinion[1]

Ketoprofen

All ruminants, porcine and *Equidae*

On 7 November 2024 the Committee for Veterinary Medicinal Products adopted an opinion[2] recommending the modification of the entry for ketoprofen in table 1 of the Annex to Regulation (EU) No 37/2010 of 22 December 2009. Maximum residue limits for ketoprofen in bovine and porcine are recommended. Furthermore, with reference to Article 5 of Regulation (EC) No. 470/2009 and in line with the criteria laid down in Commission Regulation (EU) 2017/880, the Committee agreed that the proposed maximum residue limits could be extrapolated to all ruminants and *Equidae*. Therefore, the amendment of the entry for ketoprofen in table 1 of the Annex to Regulation (EU) No 37/2010 of 22 December 2009, is recommended as follows:

Pharmaco-logically active substance	Marker residue	Animal species	MRLs	Target tissues	Other provisions	Therapeutic classification
Ketoprofen	Ketoprofen	All ruminants, porcine, *Equidae*	50 µg/kg 20 µg/kg 20 µg/kg 50 µg/kg 20 µg/kg	Muscle Fat Liver Kidney Milk	For porcine species the fat MRL relates to 'skin and fat in natural proportions'	NO ENTRY
	Ketoprofen	Poultry	10 µg/kg 30 µg/kg 10 µg/kg 10 µg/kg	Muscle Skin and fat in natural proportion Liver Kidney	Not for use in animals from which eggs are produced for human consumption	NO ENTRY

[1] Summaries of opinion are published without prejudice to the Commission Decision.
[2] Applicants may request re-examination of any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to request such re-examination within 15 days of receipt of the opinion.